Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
ReShape Lifesciences Inc. (OBLN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 10/03/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 10/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/27/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 08/25/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2023 |
4
| STANKOVICH THOMAS (CFO) has filed a Form 4 on ReShape Lifesciences Inc.|
Txns:
| Sold 109 shares
@ $2.6, valued at
$283.4
Sold 96 shares
@ $2.36, valued at
$226.6
Sold 98 shares
@ $2.41, valued at
$236.2
Bought 17,702 shares
@ $1.52, valued at
$26.9k
|
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 04/13/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/21/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 03/17/2023 |
SC 13D
| Matthew Joseph Nachtrab Revocable Trust 2014 reports a 27.7% stake in RESHAPE LIFESCIENCES INC. |
| 03/07/2023 |
4
| STANKOVICH THOMAS (CFO) has filed a Form 4 on ReShape Lifesciences Inc.|
Txns:
| Sold 48 shares
@ $7.49, valued at
$359.5
Sold 110 shares
@ $7.4906, valued at
$824
Sold 157 shares
@ $13.29, valued at
$2.1k
Sold 103 shares
@ $4.25, valued at
$437.8 |
|
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 5% stake in RESHAPE LIFESCIENCES INC. |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 02/06/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/03/2023 |
S-1MEF
| Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]: |
| 02/03/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 02/02/2023 |
RW
| Form RW - Registration Withdrawal Request: |
| 02/02/2023 |
RW
| Form RW - Registration Withdrawal Request: |
| 01/27/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/12/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 12/28/2022 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
|
|
|